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Background: Administration of the therapeutic anti-IgE antibody omalizumab to
patients induces strong increases in IgE antibody levels.
Objective: To investigate the effect of intranasal administration of major birch pol-
len allergen Bet v 1, omalizumab or placebo on the levels of total and allergen-spe-
cific IgE in patients with birch pollen allergy.
Methods: Based on the fact that intranasal allergen application induces rises of sys-
temic allergen-specific IgE, we performed a double-blind placebo-controlled pilot
trial in which birch pollen allergic subjects were challenged intranasally with omal-
izumab, placebo or birch pollen allergen Bet v 1. Total and allergen-specific IgE, IgG
and basophil sensitivity were measured before and 8 weeks after challenge. For
control purposes, total, allergen-specific IgE levels and omalizumab-IgE complexes as
well as specific IgG levels were studied in subjects treated subcutaneously with
either omalizumab or placebo. Effects of omalizumab on IgE production by IL-4/
anti-CD40-treated PBMCs from allergic patients were studied in vitro.
Results: Intranasal challenge with Bet v 1 induced increases in Bet v 1-specific IgE
levels by a median of 59.2%, and this change differed significantly from the other
treatment groups (P = .016). No relevant change in allergen-specific and total IgE
levels was observed in subjects challenged with omalizumab. Addition of omal-
izumab did not enhance IL-4/anti-CD40-induced IgE production in vitro. Significant
rises in total IgE (mean IgE before: 131.83 kU/L to mean IgE after: 505.23 kU/L)
and the presence of IgE-omalizumab complexes were observed after subcutaneous
administration of omalizumab.
Abbreviations: BCR, B-cell receptor; BSA, Bovine serum albumin; Cε3, Constant region 3; CI, Confidence interval; ELISA, Enzyme-linked immunosorbent assay; FCS, Foetal calf serum; FcεRI,
High-affinity receptor for IgE; FcRn, Neonatal Fc receptor; GMP, Good manufacturing practice; IgE, Immunoglobulin E; IL, Interleukin; ISU, International standard units; kU/L, Kilo units per
litre; kUA/L, Kilo units antigen per litre; mAb, Monoclonal antibody; MFI, Mean fluorescence intensity; PBMC, Peripheral blood mononuclear cell; PBS, Phosphate-buffered saline; RBL, Rat
basophilic leukaemia; s.c., Subcutaneous.
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Conclusion: Intranasal administration of allergen induced rises of allergen-specific
IgE levels, whereas intranasal administration of omalizumab did not enhance
systemic total or allergen-specific IgE levels.
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1 | INTRODUCTION
Immunoglobulin E (IgE) is the key antibody class responsible for aller-
gic symptoms in sensitized patients.1 Cross-linking of IgE bound to
the surface of mast cells and basophils via its high-affinity receptor
(FceRI) results in degranulation of the cells and the release of inflam-
matory mediators, cytokines and proteases.2-4
In order to prevent IgE binding to its receptors, omalizumab—a
monoclonal humanized anti-IgE antibody that specifically binds to
the constant region 3 (Ce3) of IgE—has been developed and has
been shown to be effective for the treatment of a variety of allergic
manifestations and in particular for severe IgE-mediated asthma.5-7
As the binding site of omalizumab overlaps with the binding site of
IgE to FceRI, omalizumab does not induce mast cell and basophil
activation or anaphylactic reactions and inhibits binding of circulating
IgE to its receptor on effector cells. Administration of omalizumab
therefore reduces mediator release after approximately 16 weeks of
therapy, which is associated with a downregulation of FceRI expres-
sion on basophils, mast cells and antigen-presenting cells.8-11 More
recently, it has been shown that omalizumab is also effective for the
treatment of chronic spontaneous urticaria.12
Omalizumab targets the Ce3 region of IgE, which is considered
to be accessible also on membrane-bound IgE in the form of B-cell
receptors (BCRs) on IgE+ memory B cells. It is therefore possible
that cross-linking of the BCR on IgE+ memory cells may contribute
to the strong increases in IgE levels which are observed in patients
treated with omalizumab in addition to a prolongation of the half-
life of IgE within the omalizumab-IgE immune complexes.5,13,14 In
this context, it has recently been hypothesized that the binding of
omalizumab to IgE may prevent degradation of IgE via binding of
the resulting IgE-IgG complex to the neonatal Fc receptor (FcRn)
and thus protecting it from endolysosomal degradation or that the
IgE-omalizumab complexes do not undergo pinocytosis.15 The other
hypothesis that cross-linking of the BCR by omalizumab may result
in increased IgE production is supported by the finding that injection
of anti-IgE in previously primed mice was driving a secondary IgE
response16 and that secondary IgE responses in mice could also be
boosted by repetitive B-cell epitopes which also may have cross-
linked the BCR.17 In the nasal mucosa of allergic patients, the pres-
ence of IgE+ B cells as well as plasma cells18 and local IgE produc-
tion19 have been demonstrated. In addition, a strong rise of
systemic allergen-specific IgE has been observed in subjects after
nasal administration of allergens20-23 indicating the potential pres-
ence of memory IgE+B cells in the nasal mucosa. We therefore
investigated the effect of intranasal administration of omalizumab,
allergen or placebo on allergen-specific and total systemic IgE. We
applied in a double-blind, placebo-controlled clinical study omal-
izumab to birch pollen allergic subjects intranasally and, as positive
and negative control, included allergic subjects who received intra-
nasal allergen challenge and buffer, respectively. The effects of intra-
nasal omalizumab and allergen exposure on total, allergen-specific
IgE and IgG levels as well as on basophil sensitivity were then anal-
ysed for a period of 8 weeks. In addition, we studied the effects of
subcutaneous (s.c.) omalizumab administration in allergic subjects
regarding changes in total, allergen-specific IgE and allergen-specific
IgG levels.
2 | MATERIAL AND METHODS
2.1 | Study design for intranasal challenge with
omalizumab, Bet v 1 or placebo
The study was performed over 8 weeks outside of the birch pol-
len season (November to January) as an investigator-initiated, ran-
domized, double-blind and placebo-controlled pilot study. The
study was approved by the Ethical committee of the University of
Vienna and Austrian authorities and registered in the European
Clinical Trials Database (EudraCT: 2012-004193-25) and in the
ClinicalTrial.gov data base (NCT03019237). During the screening
visit, 24 subjects between 18 and 60 years of age were assessed
(Figure 1). Fifteen subjects fulfilled all inclusion criteria and were
thus selected for the study. Those subjects were suffering from
moderate-to-severe allergic rhinitis to birch pollen for at least 2
seasons according to medical history. Birch pollen allergy was con-
firmed by skin prick test (ALK-Abello, Wedel, Germany) and mea-
surement of Bet v 1-specific IgE antibodies in serum
(ImmunoCAP, Phadia, Uppsala, Sweden). Only patients with Bet v
1-specific IgE levels higher than 3.51 kUA/l who were not previ-
ously exposed to omalizumab were included in the study. The
absence of nasal polyps or substantial deviation of the nasal sep-
tum was confirmed by anterior rhinoscopy prior to nasal challenge.
After the screening visit, patients were randomized into 3 groups
at a ratio of 1:1:1 (5 patients per group, using an online random-
ization programme provided by the Centre of Medical Statistics,
Informatics, and Intelligent Systems of the Medical University of
Vienna) for intranasal challenge with either omalizumab (Xolair!,
Novartis Pharmaceuticals Corporation, New York, NY), Bet v 1
(Biomay, Vienna, Austria) or placebo (0.9% sodium chloride
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solution). One patient in the omalizumab challenge group with-
drew from the study due to illness (upper respiratory tract infec-
tion) just before the first nasal challenge. At visit 1 (t1), blood
samples were taken and the first nasal challenge was performed.
Two more nasal challenges were performed on the consecutive
2 days. Further blood samples were taken 3 (t2), 5 (t3) and 8 (t4)
weeks (!4 days) after the first challenge. The clinical investigators
and study subjects were blinded regarding the administered sub-
stances. Randomization and preparation of the study drugs (omal-
izumab, Bet v 1 or placebo) were carried out by a person who
was not involved in the study and had no contact with the sub-
jects to ensure the double-blinded nature of the study.
2.2 | Nasal allergen challenge
Purified recombinant Bet v 1 produced according to good manufac-
turing practice (GMP) (Biomay AG) or Xolair (Novartis) was diluted in
sterile 0.9% sodium chloride freshly before use. Bet v 1 was applied
at a concentration of 50 lg/mL as this concentration has previously
been shown to lead to increase in systemic serum IgE levels after
intranasal administration.21 Omalizumab was applied at an equimolar
concentration (438 lg/mL), and 0.9% sodium chloride was applied as
placebo. Patients were administered 1 puff per nostril using a
metered pump delivering 15 lL per puff.
2.3 | Sera from subjects who had received s.c.
administration of omalizumab or placebo
Recruitment, study population, administration of the drug as well
as dosage and blood draw schedule are described in detail in
Gevaert et al.24 Sera from this study were obtained and tested in
our study as follows: sera “Before s.c. administration” were tested
at visit V1 (V1: screening visit, at least 2 weeks before visit V2
where first dose of omalizumab was administered) except for sub-
ject S9 where serum was from V2. Sera “After s.c. administration”
were tested at visit V8 (12 weeks after first subcutaneous adminis-
tration) except for subject S18 where serum from visit V6 (8 weeks
after first subcutaneous administration) and for subject S16 where
serum from visit V10 (16 weeks after first subcutaneous adminis-
tration) was tested. Skin prick tests were performed using a grass
mix, 2 different tree mixes (Betulaceae and Fagaceae), as well as
mugwort, mould, cat, dog, D. pter., D. far. extract all purchased
from Stallergenes (Antony, France).
2.4 | Measurements of total IgE, allergen-specific
IgE and allergen-specific IgG levels in sera
Total IgE and IgE specific to birch extract (t3), Bet v 1 (t215),
grass (g6), olive (t9), cat (e1) and house dust mite (d1) were
F IGURE 1 Design of the intranasal
challenge study. A, Subjects were
challenged intranasally with either
omalizumab, Bet v 1 or placebo on 3
consecutive days (d1-d3, arrows, top).
Blood samples (arrows, bottom) were taken
before the first (t1) challenge and on days
21 (t2), 35 (t3) and 56 (t4) (!4 days) after
the first challenge. B, Flow chart depicting
number of subjects who were screened
(n = 24), randomized (n = 15), and who
completed (n = 14) the study
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measured by ImmunoCAP (Phadia, Uppsala, Sweden). Allergen-spe-
cific IgG levels were analysed using a microarray based on Immu-
noCAP ISAC technology (Phadia-Thermofisher, Uppsala, Sweden)
containing more than 170 different allergen molecules25 according
to the manufacturer’s instruction.
2.5 | Basophil activation
Allergen-induced basophil activation was determined in heparinized
blood samples obtained before and after intranasal challenge by
measuring the upregulation of CD203c expression on basophils upon
exposure to rBet v 1 (0.01 lg/mL), anti-IgE (1 lg/mL) or buffer
(phosphate-buffered saline = PBS). Mean fluorescence intensities of
stimulated (MFIstim) and unstimulated (MFIcontrol) cells were deter-
mined for triplicate cultures by flow cytometry, and the upregulation
of CD203c expression was expressed as stimulation index (MFIstim:
MFIcontrol) (SI).26
In addition, basophil activation tests were performed by pas-
sive loading of rat basophilic leukaemia (RBL) cells expressing
the a/b/c subunits of the human FceRI27 with 1:20 diluted sera
from subjects obtained at different time points (t1 and t3).
Degranulation was induced by addition of rBet v 1 (0.01 lg/mL)
or buffer as control. Released b-hexosaminidase was measured,
and percentage release was calculated as described.28 All
measurements were performed in triplicates. Percentage
changes in b-hexosaminidase release between t1 and t3 were
calculated.
2.6 | ELISA measurement of omalizumab-IgE
complexes in serum
ELISA plates (ie, 384 well plates, Nunc Maxisorp, Roskilde, Den-
mark) were coated with 1 lg/mL human anti-omalizumab (drug/
target complex) HCA238 (Bio-Rad, Hercules, CA) overnight at
4°C and blocked with PBS/5% v/v BSA/0.05% v/v Tween-20
(blocking buffer). As a standard, purified monoclonal chimeric Bip
1 IgE (5 lg/mL)29 was incubated with varying concentrations of
omalizumab in PBS containing 10% v/v human serum (Lonza
Group LTD, Basel, Switzerland) as well as 0.05% v/v Tween-20.
Chimeric Bip 1 IgE standard and omalizumab were complexed at
room temperature for 1 hour before applying the standards to
the plates. Samples were diluted 1:10 in PBS with 0.05% v/v
Tween-20. Standards and samples to be analysed were added
to plates and incubated at 4°C overnight. After washing, the
HRP-conjugated human anti-omalizumab antibody (drug/target
complex) HCA237P (2 lg/mL, Bio-Rad, Hercules, CA), diluted in
HISPEC buffer (Bio-Rad, Hercules, CA), was applied to the plates
for 1 hour at RT. After thorough washing, tetramethylbenzidine
substrate (Ebioscience, San Diego, CA, USA) was applied to the
plates for the enzymatic colour reaction and stopped by addition
of 1M phosphoric acid. OD levels were read at 450 nm. Measure-
ments were performed in triplicates, and background was
subtracted.
2.7 | Isolation and cultivation of peripheral blood
mononuclear cells (PBMCs)
Heparinized blood samples were obtained from 2 birch and grass
pollen allergic subjects after written informed consent was given (ap-
proved by the Ethical committee of the Medical University of
Vienna, EK1641/2014). PBMCs were isolated from heparinized
blood samples of allergic patients using Ficoll density gradient sepa-
ration (Amersham Biosciences AB, Uppsala, Sweden). Cells were
washed 3 times in phosphate-buffered saline (PBS) (PAA Laborato-
ries, Pasching, Austria) and then cultured in RPMI 1640 containing
L-glutamine (BioWhittaker, Verviers, Belgium), supplemented with
10% foetal calf serum (FCS) (PAA Laboratories, Pasching, Austria)
and 50 lg/mL gentamicin (Sigma, St. Louis, MO, USA). Cells were
either left unstimulated or stimulated with IL-4 (400 IU/mL, R&D,
Minneapolis, MI, USA) and anti-CD40 (clone G28.5, 1 lg/mL Biole-
gend, San Diego, CA, USA) in the presence or absence of omal-
izumab (3 lg/mL) or isotype control (3 lg/mL, Southern Biotech,
Alabama, AL). Supernatants were taken after 1 week of culture and
frozen at "20°C until measurement of total IgE levels by Immuno-
CAP (total IgE low range, Phadia-Thermofisher, Uppsala, Sweden).
Percentage change in total IgE levels compared to supernatants from
unstimulated cells was calculated.
2.8 | Statistics
Statistical analyses were carried out with SAS 9.4. (SAS Institute Inc.,
Cary, NC, USA) or R 3.3.1 (The R Foundation for Statistical Comput-
ing, Vienna, Austria). For all analyses, the significance level was set
to 0.05. To analyse the percentage change among the intranasal
treatment groups, the Kruskal-Wallis test was conducted. Only if the
P-value of the Kruskal-Wallis test was < .05, the two-sided Wilcoxon
rank-sum test was calculated for pairwise group comparison. For
both, the Kruskal-Wallis test and the Wilcoxon rank-sum test, exact
P-values were computed. To analyse the difference before and after
subcutaneous administration of omalizumab, paired t tests and 95%
confidence intervals (CI) for the mean difference of visits were calcu-
lated for each treatment group separately, assuming a normal distri-
bution of the data. To assess correlation between total IgE levels
and omalizumab-IgE complexes, Pearson correlation coefficients,
95% CIs as well as exact P-values were calculated. Due to the
exploratory nature of this pilot study, no correction for multiple test-
ing was applied.
3 | RESULTS
3.1 | Design of a study to investigate the effects of
intranasal application of omalizumab on systemic IgE
levels
Allergic patients suffering from birch and grass pollen allergy
(n = 15) (Table 1, Table S1) included in the intranasal challenge study
were randomized into 3 groups (5 patients each) for intranasal
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challenge with omalizumab, Bet v 1 or placebo (Table 1, Figure 1). A
group challenged intranasally with Bet v 1 was included as a positive
control because it has been shown that intranasal challenge with Bet
v 1 induces systemic rises of Bet v 1-specific IgE levels.20-23 One
subject of the omalizumab group dropped out 1 day before intrana-
sal challenge due to a viral upper respiratory tract infection. All other
participants completed the study. Demographic, clinical and serologi-
cal data of the subjects are displayed in Tables 1 and Table S1 indi-
cating a balanced distribution of mean Bet v 1-specific and mean
total IgE levels in the 3 groups.
In addition, we investigated sera obtained from subjects before
and after receiving omalizumab (n = 15) or placebo (n = 6) subcuta-
neously24 because it has been shown that subcutaneous injection of
omalizumab induces rises of total serum IgE. These patients have
been previously described by Gevaert et al,24 and their demographic
and clinical characteristics are listed in Table S2.
3.2 | Intranasal challenge with Bet v 1 increases
allergen-specific IgE levels while intranasal
omalizumab challenge has no effect on allergen-
specific or total IgE levels
Subjects who were challenged intranasally with Bet v 1 on 3 con-
secutive days outside of the birch pollen season showed significant
increases in Bet v 1-specific serum IgE levels as compared to sub-
jects who were challenged with placebo or omalizumab (Kruskal-
Wallis test: P = .0053, two-sided Wilcoxon rank-sum test Bet v 1
vs omalizumab and Bet v 1 vs placebo: P = .016) (Figure 2A,
Table S3). The median increase in Bet v 1-specific serum IgE
observed at t3 in the Bet v 1-challenged group was 59.23% (range:
3.55%-124.60%). No relevant changes in total or Bet v 1-specific
IgE levels were observed after nasal challenge with omalizumab,
and there were no statistically significant differences in changes of
total IgE levels between t1 and t3 between the 3 treatment groups
(Kruskal-Wallis Test: P = .0521) (Figure 2B). There were also no rel-
evant changes observed for grass, olive, cat or house dust mite-
specific IgE levels between t1 and t3 between the 3 groups
(Table S3).
3.3 | Loading of basophils with sera after Bet v 1
challenge increases sensitivity but patient’s basophil
sensitivity is not increased
In a first set of experiments, we investigated whether loading of RBL
cells expressing the human FceRI with sera from subjects obtained
5 weeks after intranasal challenge with Bet v1 increases Bet v 1-speci-
fic sensitivity. We found significant group differences between the
intranasally challenged groups (Kruskal-Wallis: P = .0463). The sensi-
tivity of basophils loaded with sera from Bet v 1-challenged subjects
was significantly higher than that of basophils loaded with sera from
omalizumab-challenged subjects (pairwise Wilcoxon test: P = .032)
(Figure 3A). The sensitivity of basophils loaded with sera from Bet v 1-
challenged subjects was also greater than that of basophils loaded
with serum from placebo-challenged subjects but did not reach
significance (P = .095).
No differences regarding Bet v 1-specific sensitivity was found
when basophils from challenged subjects were obtained at t1 and t3
and compared in vitro for allergen-specific sensitivity (Figure 3B).
Basophil activation in PBMCs isolated from all subjects was mea-
sured by assessing CD203c upregulation by flow cytometry upon
addition of Bet v 1 to cells. The change between t1 and t3 was cal-
culated, but no relevant differences in basophil sensitivity were
observed between the treatment groups (Kruskal-Wallis test:
P = .1934) (Figure 3B).
TABLE 1 Summary of the demographic and clinical characterization of study subjects
Characteristic
i.n. challenge groups
Omalizumab (n = 4) Bet v 1 (n = 5) Placebo (n = 5)
Male/Female 0/4 2/3 1/4
Age (y)
Mean ! SD 23.5 ! 2.7 28.4 ! 6.2 28.4 ! 9.9
Range 21-27 22-35 22-46
Allergic symptoms -no (%)
Rhinitis 4 (100) 5 (100) 5 (100)
Conjunctivitis 3 (75) 5 (100) 5 (100)
Atopic dermatitis 0 (0) 2 (40) 5 (100)
Total IgE (kU/L)
Mean ! SD 449 ! 440 285 ! 193 429 ! 262
Range 61.4-954 101-549 129-699
Bet v 1-spec. IgE (kUA/L)
Mean ! SD 24.7 ! 21.7 22.9 ! 15.7 29.8 ! 10.6
Range 9.4-55.5 5.5-43.9 12.2-39.6
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3.4 | Subcutaneous application of omalizumab
induces a rise in total IgE and the presence of IgE-
omalizumab complexes in the serum
The analysis of sera from subjects who had received subcutaneous
administration of omalizumab (n = 15) or placebo (n = 6)24 showed a
significant rise in mean total IgE levels, that is mean 131.83 kU/L
before to 505.23 kU/L, after administration of omalizumab (mean
difference [95% CI]: 373.40 [264.23; 482.58], P < .0001, n = 15)
(Figure 4A). In patients who had received placebo s.c., no significant
differences regarding IgE levels before and after application were
observed (mean difference [95% CI]: 7.86 [-9.10; 24.81], P = .29,
n = 6).
When we analysed allergen-specific IgE levels, a fourfold to sev-
enfold rise in allergen-specific IgE was observed after subcutaneous
administration of omalizumab but not of placebo regardless of the
nature of the tested allergen (Table S4). Interestingly, in 3 patients,
allergen-specific IgE rose over the cut-off level of 0.35 kUA/L for
IgE measurements after subcutaneous omalizumab administration (ie,
cat-specific IgE: subject S6: 0.28 (before treatment) ? 2.07 (after
treatment) kUA/L; house dust mite-specific IgE: subject S7: 0.11 ?
0.43 kUA/L and subject S9: 0.11 ? 0.37 kUA/L). As already
reported in another study, it seems that administration of omal-
izumab can reveal an already existing IgE sensitization below the
cut-off levels of IgE tests.13
Using an ELISA based on antibodies recognizing specifically IgE-
omalizumab complexes but neither noncomplexed IgE nor noncom-
plexed omalizumab alone, omalizumab-IgE complexes were detected
in the sera from all subjects after subcutaneous omalizumab adminis-
tration. The levels of IgE-omalizumab complexes rose significantly
from 0 lg/mL before to an average of 0.104 lg/mL in subjects
receiving omalizumab (Figure 4B: mean difference [95% CI]: 0.104
[0.051; 0.157], P = .0009, n = 15). A statistically significant correla-
tion between serum IgE levels and the amount of IgE-omalizumab
complexes was noted; however, the corresponding confidence inter-
val is wide due to the low sample size (Figure 4C: Pearson correla-
tion coefficient [95% CI]: 0.54 [0.04; 0.83], P = .0359, n = 15).
3.5 | Neither intranasal nor subcutaneous
application of omalizumab affects allergen-specific
IgG levels
We also analysed allergen-specific IgG levels in sera obtained from
subjects before and after intranasal or subcutaneous application of
omalizumab using a microarray containing more than 170 different
allergens.25 There were no consistent and no significant changes in
allergen-specific IgG levels after intranasal or after subcutaneous
application of omalizumab, Bet v 1 or placebo for Bet v 1, Phl p 1,
Phl p 5, Ole e 1, Fel d 1 and Der p 1 (Table S5; Fig. S1).
3.6 | Omalizumab does not increase IgE production
induced in allergic patients’ PBMCs stimulated with
anti-CD40/IL-4 in vitro
To further investigate the potential effect of omalizumab on IgE pro-
duction in vitro, we stimulated PBMCs derived from allergic subjects
(Subject 1 and 2) with anti-CD40 and IL-4 in the presence or
absence of omalizumab as well as an isotype control for omalizumab.
Anti-CD40 and IL-4 stimulation induced an increase in total IgE
levels in culture supernatants of both allergic subjects as previously
described30,31 (Fig. S2). Addition of omalizumab had no relevant
effect on IgE production in the PBMC cultures.
4 | DISCUSSION
In the present study, we investigated the effect of intranasal admin-
istration of Bet v 1, omalizumab and placebo on the levels of total
and allergen-specific IgE in patients with birch pollen allergy. The
F IGURE 2 Percentage change in total and Bet v 1-specific serum
IgE levels following intranasal challenge with omalizumab, Bet v 1 or
placebo. Percentage changes (y-axes) of (A) Bet v 1-specific and (B)
total IgE levels between t1 (before challenge) and t3 (day 35 ! 4 days
after challenge) are shown for each subject. Significant differences
between the treatment groups were observed only for Bet v 1-specific
IgE (Kruskal-Wallis test: P = .0053) levels but not for total IgE levels
(Kruskal-Wallis test: P = .0521). Pairwise comparisons using the two-
sided Wilcoxon rank-sum test were therefore only performed for Bet
v 1-specific IgE levels and P values are indicated
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pilot clinical trial performed by intranasal administration of Bet v 1
and omalizumab was based on the observation that intranasal admin-
istration of allergen to allergic patients induced a robust increase in
allergen-specific IgE antibodies, eventually by targeting IgE-producing
cells.20-23 In fact, histological analyses of nasal mucosal biopsies have
revealed the presence of IgE+ B cells and plasma cells in the nasal
mucosa.18 Furthermore, Se switch circles have been found in nasal
biopsies after ex vivo allergen challenge suggesting local synthesis of
IgE in the nasal mucosa.19 We therefore hypothesized that IgE-pro-
ducing B cells in the nasal mucosa are the source of the allergen-
induced systemic IgE rises and can be reached and stimulated via
the intranasal route. Indeed, we were able to demonstrate that nasal
administration of the major birch pollen allergen Bet v 1 led to a
significant increase in Bet v 1-specific IgE levels 5 weeks after the
challenge. Interestingly, these increases in Bet v 1-specific IgE levels
observed after 5 weeks did not lead to increased basophil sensitivity
when basophils of allergic patients were exposed to the Bet v 1
allergen. In contrast, when we passively sensitized basophils with
serum taken at the same time, an increased Bet v 1-specific basophil
sensitivity was observed.
There are several mutually not exclusive explanations why there
are differences regarding allergen-specific sensitivity when testing
allergic patients basophils isolated at different time points from the
patients vs testing cultured basophils. First, it is possible that the
intrinsic sensitivity of the patient’s basophils may vary at different
time points. Second, testing of patients basophils at different time
points may introduce variation. Third, experiments with patient’s
basophils are carried out in the presence of allergen-specific IgG. In
fact, allergen-specific IgG increases were noted in several serum
samples which may have affected allergen-induced basophil activa-
tion (Table S5). Finally, it is possible that at the time points
investigated (ie, t1 and t3) the newly produced IgE was not yet fully
loaded onto the patients basophils which were preoccupied with the
IgE which was there before.
The results can thus be summarized as follows: intranasal appli-
cation of the major birch pollen allergen Bet v 1 led to an increase
in allergen-specific but not total systemic IgE levels, while intranasal
omalizumab application had no effect on total or allergen-specific
IgE levels. Basophil sensitivity in patients did not change after
challenge with the allergen despite a significant increase in Bet v
1-specific IgE levels. In contrast, rat basophilic leukaemia cells
expressing the human FceRI which had been passively sensitized
with the sera from allergen-challenged patients showed increased
allergen sensitivity after the challenge.
Furthermore, our in vitro experiments showed that omalizumab
had no effect on the secretion of IgE ex vivo using PBMCs primed
with IL-4 and anti-CD40. In patients having undergone subcuta-
neous omalizumab administration, a significant rise in systemic IgE
levels and the presence of IgE-omalizumab complexes were demon-
strated. In summary, these data suggest that the rise of systemic
IgE levels observed in omalizumab-treated patients is most likely
due to the formation of IgE-omalizumab complexes increasing the
half-life of IgE and not due to an increase in IgE production by
IgE+ B cells.
We have thus addressed two mutually nonexclusive possibilities
to explain the rises of IgE levels in allergic patients undergoing ther-
apy with the monoclonal anti-IgE antibody omalizumab. The first
possibility is based on findings that the administration of anti-IgE
antibodies into primed mice16 as well as injection of oligomeric aller-
gen derivatives17 which are able to cross-link the BCR on IgE-produ-
cing memory cells into sensitized mice can boost secondary IgE
production. This hypothesis has been controversially discussed with
F IGURE 3 Effects of changes of allergen-specific IgE levels on basophil activation. (A) Rat basophilic leukaemia (RBL) cells expressing
human FceRI were loaded with sera obtained at t1 and t3 and then stimulated with Bet v 1. Percentage changes (y-axes) of b-hexosaminidase
release between t3 and t1 are shown. (B) Peripheral mononuclear cells (PBMCs) from subjects challenged intranasally (x-axis: omalizumab, Bet
v 1 or placebo) were stimulated with Bet v 1. Differences in the stimulation indices for the upregulation of CD203c between t3 and t1 are
shown as percentage changes (y-axes). Significant differences between the 3 treatment groups were observed for the RBL assay (Kruskal-
Wallis test: P = .0463) shown in (A) but not for the assays using basophils directly collected from subjects (Kruskal-Wallis test: P = .1934)
shown in (B). Pairwise comparisons using the two-sided Wilcoxon rank-sum test were therefore only performed for the RBL assay and P-
values are indicated
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arguments in favour14,16,32,33 and against34,35 the potential of omal-
izumab to activate IgE+ memory B cells. In the present study, both in
our in vivo intranasal challenge model and in our in vitro approach
using a well-established system to induce IgE production,30,31 we did
not observe any enhancing effect of omalizumab on IgE production.
Results from the in vitro experiments indicate that omalizumab is
not able to activate IgE-producing cells by cross-linking of the IgE-
BCR. This is in line with a study of Chan et al investigating the
effect of omalizumab on the presence of IgE+ B cells and Ce germ-
line transcription but not IgE production in vitro as we did.34 They
observed even a slight decrease in IgE+ B-cells numbers upon addi-
tion of omalizumab to the cultures. Limitations of our study include
that only a limited number of patients and only 1 administration
schedule were studied in vivo and regarding the in vitro experiments
that the IL-4/anti-CD40-switched IgE-producing cells may not
exactly mimic IgE-BCR containing memory B cells. However, both
the in vivo and the in vitro experiments did not provide evidence
that omalizumab induces IgE production through activation of IgE-
producing cells.
The other hypothesis for the increase in IgE upon omalizumab
administration which has been proposed recently suggests that com-
plex formation between IgE and omalizumab, a human monoclonal
IgG1 antibody, prolongs the serum half-life of IgE by preventing its
degradation utilizing the recycling of the complex by the neonatal
receptor for IgG, FcRn.15,36,37 The latter hypothesis is difficult to
test in allergic patients because it would require the administration
of labelled IgE-omalizumab immune complexes and a subsequent
analysis of the half-life of IgE as well as tracing of the complexes
in vivo at an ultra-structural level. We therefore performed an analy-
sis of sera from subjects who had received s.c. omalizumab or pla-
cebo administration24 regarding allergen-specific IgE levels to a large
number of allergens using microarray technology25 (data not shown)
and quantitative ImmunoCAP measurements. We found that the
administration of omalizumab increased IgE to all allergens the
patients was already sensitized to but no relevant new IgE sensitiza-
tions were noted. Only in 3 patients, IgE sensitization to cat and
mite allergens exceeding cut-off IgE levels was noted. This observa-
tion is in line with a recent study conducted by Mizuma et al.,
F IGURE 4 Total serum IgE and IgE-
omalizumab complex levels in subjects
after subcutaneous omalizumab
administration. (A) Total serum IgE levels
(y-axis: kU/L) and (B) levels of IgE-
omalizumab complexes (y-axis: lg/mL) in
subjects before and after subcutaneous
administration of omalizumab (left, n = 16)
or placebo (right, n = 6). Sera “Before s.c.
administration” were obtained at visit V1
(V1: screening visit, at least 2 weeks
before visit V2 where first dose of
omalizumab was administered) except for
subject S9 where serum was obtained at
V2. Sera “After s.c. administration” were
obtained at visit V8 (12 weeks after first
subcutaneous administration) except for
subject S18 where serum obtained at visit
V6 (8 weeks after first subcutaneous
administration) and for subject S16 where
serum was obtained at visit V10 (16 weeks
after first subcutaneous administration). (C)
Correlation of total IgE levels (x-axis) with
IgE-omalizumab complexes (y-axis) is
displayed for patients after subcutaneous
omalizumab administration. Significant
results (P-values) are indicated
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where the authors described patients while exhibiting Japanese
cedar-specific IgE levels above 0.35 kU/L only after omalizumab
therapy had already suffered from cedar pollinosis before ther-
apy.13,14 Using an assay able to distinguish IgE-omalizumab com-
plexes from IgE and omalizumab alone, we could demonstrate the
formation of IgE-omalizumab complexes after subcutaneous omal-
izumab administration, which correlated to some extent with the
increase in total IgE. These results indeed suggest that the rise in
total IgE levels upon omalizumab administration is most likely due to
IgE-omalizumab complex formation resulting in prolongation of the
otherwise relatively short half-life of IgE.15,38,39
In summary, our results indicate that increases in IgE levels under
omalizumab treatment are not due to cross-linking of the BCR on
IgE+ memory cells causing increased IgE production but rather due
to formation of nonallergenic omalizumab-IgE complexes with pro-
longed serum half-life.
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